Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EntreMed Hopes To Partner, Rapidly Advance Promising Kinase Inhibitor

This article was originally published in The Pink Sheet Daily

Executive Summary

With no revenue for first half of 2008, finding a partner is crucial to development of EMND-2076.

You may also be interested in...



Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva

Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.

Troubled Biotechs: Adventrx, EntreMed, Peregrine, Anesiva

Adventrx enacts second staff reduction to continue operations as top two candidates near FDA filing.

EntreMed Panzem To Boost Bioavailability Under Elan Supply Deal

Elan will reformulate and manufacture Panzem (2-methoxyestradiol) as an oral liquid formulation using its NanoCrystal technology. EntreMed expects to initiate a clinical oncology program in 2005 using the new formulation.

Related Content

Topics

UsernamePublicRestriction

Register

PS068212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel